RCT: Among critically ill patients with Covid-19, treatment with an antiplatelet agent had a low likelihood of improving organ support–free days within 21 days.

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial – JAMA

Editorial: Thromboinflammation and Antithrombotics in COVID-19: Accumulating Evidence and Current Status – JAMA

Commentary: Aspirin may improve 3-month survival for patients critically ill with COVID-19 – Imperial College London

Commentaries on Twitter

In this bayesian randomized clinical trial, among critically ill patients with #COVID19, there was a low likelihood that treatment with an antiplatelet agent provided improvement in organ support–free days within 21 days. https://t.co/CnyWoOTn3Q

— JAMA (@JAMA_current) March 22, 2022